Gilead Buying Liver Disease Drugmaker CymaBay For $4.3B

By Al Barbarino · February 12, 2024, 1:24 PM EST

Gilead Sciences Inc. said Monday that it has agreed to purchase liver disease-focused clinical-stage biopharmaceutical company CymaBay Therapeutics Inc. for $4.3 billion in cash....

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Recent Articles By Al

October 30, 2024
Kirkland-Led Francisco Paying $1.1B For AdvancedMD
October 28, 2024
Crown Settles Customer Dispute To Close $924M Revance Buy
October 18, 2024
FTC Faces More Pressure To Block $16.5B Novo-Catalent Deal
October 10, 2024
Sen. Warren, Novo At Odds On Merits Of $16.5B Deal
August 20, 2024
J&J Boosting Cardio Portfolio With Up To $1.7B V-Wave Buy
August 13, 2024
3 Firms Drive $3.8B Carlyle-Baxter Kidney Care Deal
August 01, 2024
R1 RCM Going Private In $8.9B Deal Steered By 4 Firms
July 09, 2024
Kirkland Guides Avesi Partners To $1.35B Fund II Close
July 02, 2024
DLA Piper Hires Former Goodwin Corporate Partner In DC
June 27, 2024
AbbVie Buys Bowel Disease Biotech Celsius For $250M